ACG appoints Lalit Kasliwal as Group Chief Financial Officer
Kasliwal to lead global finance, governance, capital allocation and risk management as ACG expands its international presence
ACG has appointed Lalit Kasliwal as Group Chief Financial Officer, with responsibility for the company’s global finance function across its pharmaceutical and nutraceutical manufacturing businesses.
In his new role, Kasliwal will lead financial strategy, treasury, governance, capital allocation and risk management to support ACG’s long-term ambitions.
Kasliwal brings more than 27 years of global leadership experience across financial strategy, treasury, capital allocation and structuring, governance, enterprise transformation and risk management in the pharmaceutical, manufacturing and international trading sectors.
He joins ACG from Tata International Limited, where he served as Chief Financial Officer and Company Secretary, leading the global finance function for operations across more than 29 countries. Before this, he served as CFO – Group Manufacturing and Head of Group Insurance at Reliance Industries Limited. Earlier in his career, he held senior finance leadership positions with Vedanta Group, including Hindustan Zinc Limited and Sterlite Technologies Limited, Ruia Group and IPCA Laboratories Limited.
Karan Singh, Managing Director at ACG, commented; “We are delighted to welcome Lalit to ACG. He brings a wealth of global experience, a strong track record of financial leadership and a deep understanding of complex international businesses. His expertise will be invaluable as we continue to strengthen our operations and pursue the next phase of our growth strategy.”
Lalit Kasliwal added; “I am delighted to be joining ACG at an exciting stage of its global growth journey. I look forward to partnering with colleagues across the organisation to strengthen financial performance, enhance governance and support sustainable long-term value creation for our customers, partners and stakeholders.”
The appointment comes as ACG continues to expand its global presence and invest in technologies and solutions that support pharmaceutical and nutraceutical manufacturers worldwide.